ARTUSI, Carlo Alberto
 Distribuzione geografica
Continente #
NA - Nord America 4.165
EU - Europa 2.277
AS - Asia 1.017
OC - Oceania 61
SA - Sud America 55
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 9
Totale 7.629
Nazione #
US - Stati Uniti d'America 4.093
IT - Italia 573
CN - Cina 564
IE - Irlanda 359
SE - Svezia 315
DE - Germania 156
FR - Francia 151
GB - Regno Unito 127
BE - Belgio 106
JP - Giappone 88
ES - Italia 78
VN - Vietnam 76
NL - Olanda 68
FI - Finlandia 67
CA - Canada 61
KR - Corea 61
IN - India 59
AU - Australia 54
PL - Polonia 53
AT - Austria 46
TR - Turchia 43
UA - Ucraina 35
TW - Taiwan 31
BR - Brasile 30
CH - Svizzera 27
HK - Hong Kong 20
PT - Portogallo 20
SN - Senegal 19
RO - Romania 18
IR - Iran 14
RU - Federazione Russa 12
CZ - Repubblica Ceca 11
GR - Grecia 11
IL - Israele 11
BG - Bulgaria 10
DK - Danimarca 10
EG - Egitto 9
ID - Indonesia 9
MX - Messico 9
UZ - Uzbekistan 8
CL - Cile 7
CO - Colombia 7
EU - Europa 7
NZ - Nuova Zelanda 7
SG - Singapore 6
ZA - Sudafrica 6
AR - Argentina 5
IS - Islanda 5
NO - Norvegia 5
PH - Filippine 5
TH - Thailandia 5
EC - Ecuador 3
HU - Ungheria 3
MU - Mauritius 3
MY - Malesia 3
NG - Nigeria 3
PE - Perù 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
BN - Brunei Darussalam 2
CY - Cipro 2
EE - Estonia 2
HN - Honduras 2
KZ - Kazakistan 2
SA - Arabia Saudita 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BY - Bielorussia 1
DZ - Algeria 1
GH - Ghana 1
HR - Croazia 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
NP - Nepal 1
PK - Pakistan 1
RS - Serbia 1
Totale 7.629
Città #
Chandler 695
Dublin 357
Beijing 280
Fairfield 235
Ashburn 197
Torino 181
Nyköping 168
Houston 148
Redwood City 135
Wilmington 133
Ann Arbor 131
Medford 108
Seattle 108
Princeton 103
Woodbridge 102
Cambridge 88
Fremont 86
Villeurbanne 81
Brussels 72
Dearborn 70
Jacksonville 66
Dong Ket 53
Boston 42
Pisa 42
Vienna 42
Hangzhou 40
Turin 39
New York 38
Warsaw 33
Milan 29
Seoul 27
Boardman 24
Guangzhou 21
Madrid 21
Ottawa 21
Shanghai 21
Taipei 20
Chengdu 19
Norwalk 18
Rome 18
San Diego 17
Hebei 16
Istanbul 16
Washington 15
Nanjing 13
Tokyo 13
Jinan 12
London 12
Toronto 12
Changsha 10
Hong Kong 10
Chicago 9
Duncan 9
Amsterdam 8
Düsseldorf 8
Falls Church 8
Genoa 8
Hefei 8
Oxford 8
Paris 8
Pune 8
Renton 8
Sydney 8
Barcelona 7
Edinburgh 7
Helsinki 7
Kunming 7
Melbourne 7
Minneapolis 7
Polska 7
Wuhan 7
Zhengzhou 7
Brno 6
Cincinnati 6
Gazi 6
Groslay 6
Hanover 6
Nashville 6
Pamplona 6
Riverton 6
Rochester 6
Valencia 6
Antwerp 5
Bethesda 5
Bologna 5
Curitiba 5
Gainesville 5
Köln 5
Mountain View 5
New Delhi 5
Northvale 5
Phoenix 5
Saint Paul 5
Salt Lake City 5
Santiago 5
Upper Marlboro 5
Utrecht 5
Zurich 5
Bengaluru 4
Chongqing 4
Totale 4.567
Nome #
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. 686
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience 422
Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study. 319
Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. 302
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 285
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome? 253
80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements. 250
Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset? 240
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients 234
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry 174
Natalizumab in Multiple Sclerosis: Long-Term Management 128
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 123
Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail 118
Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic 115
Neurological comorbidity and severity of COVID-19 98
Safety and efficacy of tolcapone in Parkinson’s disease: systematic review 97
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 87
Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study 87
3 years comparison between duodopa and Deep Brain Stimulation 78
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 78
Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications 76
Pisa syndrome in Parkinson's disease is associated with specific cognitive alterations 71
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 70
Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming 70
Beyond Nine Years of Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease 69
Earlier versus later subthalamic deep brain stimulation in Parkinson's disease 69
Orthostatic hypotension in Parkinson disease: Impact on health care utilization 69
Continuous intraduodenal L-dopa/carbidopa gel infusion improves nocturnal sleep in advanced Parkinson’s disease 66
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 66
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 66
The dominant subthalamic nucleus: A gait analysis study 63
Complex therapies for advanced Parkinson’s disease: what is the role of doctor-patient communication? 63
Deep brain stimulation fine-tuning in Parkinson's disease: Short pulse width effect on speech 63
Ultrasound-guided botulinum toxin-A for sialorrhea: a 2-year prospective study 62
Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study 62
Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson’s Disease? 62
The still under-investigated role of cognitive deficits in PML diagnosis 62
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease 61
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 61
Clinical efficacy of different stimulation frequencies on dyskinesias and dystonias in subthalamic nucleus deep brain stimulation patients with parkinson's disease 58
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 58
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 58
Effects of 80 Hz stimulation on gait in STN-DBS treated PD patients 57
Changing the Side of Pisa Syndrome: A Case of Over-Recovery with Botulinum Toxin 57
Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution 57
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors 55
Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic 55
Parkinsonism–hyperpyrexia syndrome and deep brain stimulation 55
A new index to assess turning quality and postural stability in patients with Parkinson's disease 54
COVID-19 and Parkinson's Disease: What We Know So Far? 54
Low frequency subthalamic stimulation and event-related potentials in Parkinson disease 51
Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease 51
Motor and non-motor outcomes of subthalamic deep brain stimulation in a case of juvenile PARK-PINK1 51
Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia 50
Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease 50
Peripheral neuropathy in Parkinson’s disease patients treated with duodenal levodopa/carbidopa infusion: A clinical and electrophysiological follow-up study 49
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis 49
Home monitoring of motor fluctuations in Parkinson’s disease patients 48
Differential response to pallidal deep brain stimulation among monogenic dystonias: Systematic review and meta-analysis 48
Onset of Covid-19 with impaired consciousness and ataxia: a case report 48
Friedreich's ataxia patients and caregivers information seeking behaviour 47
Tuning Deep Brain Stimulation related depression by frequency modulation: a case report 47
COVID-19 in Parkinson's disease: Report on prevalence and outcome 46
Time to onset and duration of botulinum toxin efficacy in movement disorders 45
Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential 44
Prevalence and burden of dysautonomia in advanced Parkinson's disease 43
Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson’s disease 43
Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum 42
Parkinson's clinical features after 30 years of disease: A study from patients treated by subthalamic nucleus stimulation 41
Telemedicine in Neurological Disorders: Opportunities and Challenges 41
Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis 40
Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD 40
Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic 39
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease 39
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach 38
Neurological comorbidities and COVID-19-related case fatality: A cohort study 38
Focal seizures with impaired awareness as long-term neurological complication of COVID-19: a case report 38
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials 36
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study 35
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 35
Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer's Disease: Implications for Treatment 35
Subthalamic deep brain stimulation and trunk posture in Parkinson's disease 34
Prospective assessment of peripheral neuropathy in duodopa treated patients 33
G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome 33
Levodopa-Induced Neuropathy: A Systematic Review 32
Improving the care of Rebif® treated Multiple Sclerosis patients: the "MSdialog" experience 31
Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study 30
Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection 30
Digital work engagement among Italian neurologists 30
Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety 29
Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects 28
Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases 26
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach 25
Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease 18
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up 17
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review 17
Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease 17
Gait and axial postural abnormalities correlations in Parkinson's disease: A multicenter quantitative study 15
Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study 13
Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease? 13
Totale 7.861
Categoria #
all - tutte 21.980
article - articoli 0
book - libri 0
conference - conferenze 2.857
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.837


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019297 0 0 0 0 0 0 0 0 36 78 125 58
2019/2020916 42 41 40 121 84 101 100 87 79 79 73 69
2020/20211.090 63 79 59 137 82 108 46 79 98 87 85 167
2021/20221.279 81 44 52 98 75 62 64 61 53 94 317 278
2022/20231.968 203 196 52 222 166 463 134 119 167 74 111 61
2023/2024712 122 165 46 54 65 137 35 84 4 0 0 0
Totale 7.924